Make Informed Investment Decisions with Affordable Access to Experts
Discussing the Landscape of the Injectable Long-Acting Insulin Market for Merck's Glargine (MK-1293) in Type 1 & 2 Diabetes Following Expected April PDUFATicker(s): MRK, SNY, LLY, NVO
An endocrinologist who focuses on treating patients with type 1 & 2 diabetes, and has a deep knowledge of the long-acting injectable insulin market.
Please describe your background treating patients with type 1 & type 2 diabetesAdded By: pjloria
How many patients do you see for type 1 diabetes? For type 2?Added By: pjloria
What are your current methods used for treating your patients with both types of diabetes?Added By: pjloria
What medications are most commonly used currently in your practice? How would you describe the differences between these medications and how they benefit your patients?Added By: pjloria
Please discuss current long-acting injectable insulin treatments on the market, including Lilly's Basaglar, Sanofi's Lantus and Toujeo, and Novo's Levemir and Tresiba. How are they differentiated and is there any data behind any of those drugs that is particularly interesting to you?Added By: pjloria
How would Merck's Glargine fit into that market if it is approved by the FDA?Added By: pjloria
Are there any products being developed that could disrupt the long-acting injectable insulin market?Added By: pjloria
How do you see the market share for these products changing over the next couple of years? What products do you think will be dominant in the long-acting injectable insulin market?Added By: pjloria
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes MRK, SNY, LLY, NVO Occurred On: Jul 20, 2017